4 completed. 4 Phase 2, 2 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 4 |
| Phase 1 | 2 | Completed 2 |
| Phase 3 | 1 | Completed 1 |
Follow T Cell Lymphoma: new trials by email Literature Review of T Cell Lymphoma trials Research Report on T Cell Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed/Refractory Hematologic Malignancies CTX131 - T Cell Lymphoma, B Cell Lymphoma | Phase 1 / Phase 2 | Completed | CRISPR Therapeutics | 12 | 2024-08-13 | 2026-04-03 |
| Safety and Efficacy of Tenalisib (RP6530) in Combination With Romidepsin in Patients With Relapsed/Refractory T-cell Lymphoma Tenalisib, Romidepsin - T Cell Lymphoma | Phase 1 / Phase 2 | Completed | Rhizen Pharmaceuticals SA | 33 | 2019-03-12 | 2022-10-28 |
| Efficacy and Safety Study of Fostamatinib Disodium Tablets to Treat T-Cell Lymphoma Fostamatinib Disodium - T Cell Lymphoma | Phase 2 | Completed | Rigel Pharmaceuticals | 18 | 2009-03-01 | 2016-09-19 |
| HuMax-CD4 in Non-Cutaneous T-Cell Lymphoma HuMax-CD4 - T Cell Lymphoma | Phase 2 / Phase 3 | Completed | Emergent BioSolutions | 21 | 2005-08-01 | 2024-03-18 |
Lymphoma, T-Cell (4) · Leukemia (1) · Leukemia, Myeloid, Acute (1) · Lymphoma (1) · Lymphoma, B-Cell (1)
Hemic and Lymphatic Diseases (4) · Immune System Diseases (4) · Immunoproliferative Disorders (4) · Lymphatic Diseases (4) · Lymphoma, Non-Hodgkin (4) · Lymphoproliferative Disorders (4) · Neoplasms (4) · Neoplasms by Histologic Type (4) · Lymphoma (3) · Hematologic Diseases (1) · Leukemia, Myeloid (1)
fostamatinib (1) · romidepsin (1) · tenalisib (1) · zanolimumab (1)
CRISPR Therapeutics (1) · Emergent BioSolutions (1) · Rhizen Pharmaceuticals SA (1) · Rigel Pharmaceuticals (1)
United States (3) · Australia (1) · Canada (1)
Abhay Patki, PhD (1) · Alissa Keegan, MD, PhD (1) · Jeffrey Skolnik, MD (1)